Statistical considerations for multiplicity in confirmatory protocols

Drug Information Journal

Volumn 30, Issue 2, 1996, Pages 523-534

  Koch, Gary G ^a   Gansky, Stuart A ^a  

^a IL   (United States)

Author keywords

Closed testing procedure; Multiple endpoints; Multiple treatments; Significance level spending function; Subgroups

Indexed keywords

PREVALENCE; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; STATISTICAL ANALYSIS; STATISTICS;

EID: 0029930697     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286159603000228     Document Type: Review

References (26)

1. Koch GG, Amara IA, Forster J, McSorley D, Peace KE. Statistical issues in the design and analysis of ulcer healing and recurrence studies. Drug Inf J. 1993;17:805-824.
2. Elashoff JD, Koch GG. Statistical methods in trials of anti-ulcer drugs. In: Swabb EA, Szabo S, eds. Ulcer Disease Investigation and Basis for Therapy. New York: Marcel Dekker, Inc.; 1991:375-406.
3. O'Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics. 1984;40:1079-1087.
4. Lehmacher W, Wassmer G, Reitmeir P. Procedures for two-sample comparisons with multiple endpoints controlling the experimentwise error rate. Biometrics. 1991;47:511-521.
5. Koch GG, Carr GJ, Amara IA, Stokes ME, Uryniak TJ. Categorical data analysis. In: Berry DA, ed. Statistical Methodology in the Pharmaceutical Sciences. New York: Marcel Dekker, Inc.; 1990;389-473.
6. Koch GG. Comment. Stat Med. 1991;10:13-16.
7. Bauer P. Multiple testing in clinical trials. Stat Med. 1991;10:871-890.
8. Gansky SA, Koch GG, Wilson J. Statistical evaluation of relationships between analgesic dose and ordered ratings of pain relief over an eight-hour period. J Biopharm Stat. 1994;4(2):233-265.
9. Phillips JA, Cairns V, Koch GG. The analysis of a multiple-dose, combination-drug clinical trial using response surface methodology. J Biopharm Stat. 1992;2(1):49-67.
10. Koch GG. Discussion. Biopharm Report. 1993;2(1):7-8.
11. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549-556.
12. DeMets DL, Lan KKG. Interim analysis: The alpha spending function approach. Stat Med. 1994;13(13/14):1341-1352.
13. Koch GG, Edward S. Clinical efficacy trials with categorical data. In: Peace KE, ed. Biopharmaceutical Statistics for Drug Development. New York: Marcel Dekker; 1988:403-457.
14. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-748.
15. Mantel N. Chi-square tests with one degree of freedom: Extensions of the Mantel-Haenszel procedure. J Am Stat Assoc. 1963;58:690-700.
16. Koch GG, Amara IA, Davis GW, Gillings DB. A review of some statistical methods for covariance analysis of categorical data. Biometrics. 1982;38:563-595.
17. Kurtiz SJ, Landis JR, Koch GG. A general overview of Mantel-Haenszel methods: Applications and recent developments. Ann Rev Pub Health. 1988;9:123-160.
18. Koch GG, Sollecito WA. Statistical considerations in the design, analysis, and interpretation of comparative clinical studies: An academic perspective. Drug Inf J. 1984;18:131-151.
19. Fleiss JL. The Design and Analysis of Clinical Experiments. New York: Wiley; 1986.
20. Holm S. A simple sequentially rejective multiple test procedure. Scandinavian J Stat. 1979;6:65-70.
21. Shaffer J. Modified sequentially rejective multiple test problems. J Am Stat Assoc. 1986;81:826-831.
22. Hailperin R. Best possible inequalities for the probability of a logical function of events. Am Math Monthly. 1965;72:343-359.
23. 0 ab, wenn k unter n gegebenen tests zur ablehnung führen." Metrika. 1978;25:171-178.
24. Westfall PH, Young SS. Resampling-based Multiple Comparison Testing: Examples and Methods for p-Value Adjustment. New York: Wiley; 1993.
25. Lachin J. Some large-sample distribution-free estimators and tests for multivariate, partially incomplete data from two populations. Stat Med. 1992;11:1151-1170.
26. Gillings D, Koch GG. The application of intention-to-treat to the analysis of clinical trials. Drug Inf J. 1991;25:411-424.